---
title: "Pimavanserin - Parkinson'S Disease"
sidebar: mydoc_sidebar
permalink: db05316-mesh-d010300-1.html
toc: false 
---


Path ID: `DB05316_MESH_D010300_1`
{% include image.html url="images/db05316-mesh-d010300-1.png" file="db05316-mesh-d010300-1.png" alt="db05316-mesh-d010300-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C510793 | Pimavanserin | Drug |
| UniProt:P28223 | 5-hydroxytryptamine receptor 2A | Protein |
| MESH:D012701 | Serotonin | ChemicalSubstance |
| GO:0060096 | Serotonin secretion, neurotransmission | BiologicalProcess |
| HP:0000709 | Psychosis | PhenotypicFeature |
| MESH:D010300 | Parkinson's disease | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Pimavanserin | DECREASES ACTIVITY OF | 5-Hydroxytryptamine Receptor 2A |
| 5-Hydroxytryptamine Receptor 2A | POSITIVELY CORRELATED WITH | Serotonin |
| Serotonin | POSITIVELY CORRELATED WITH | Serotonin Secretion, Neurotransmission |
| Serotonin Secretion, Neurotransmission | POSITIVELY CORRELATED WITH | Psychosis |
| Psychosis | OCCURS IN | Parkinson'S Disease |
|---------|-----------|---------|

Comment: Pimavanserin is used for the treatment of hallucinations and delusions caused by Parkinson's Disease.

Reference: 
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2111101/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2111101/)
  - [https://go.drugbank.com/drugs/DB05316#BE0000451](https://go.drugbank.com/drugs/DB05316#BE0000451)
  - [https://pubmed.ncbi.nlm.nih.gov/27686027/](https://pubmed.ncbi.nlm.nih.gov/27686027/)
